<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114383">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02006667</url>
  </required_header>
  <id_info>
    <org_study_id>ML17600</org_study_id>
    <nct_id>NCT02006667</nct_id>
  </id_info>
  <brief_title>A Study of Herceptin (Trastuzumab) Combination Therapy in Patients With Metastatic Urothelial Cancer</brief_title>
  <official_title>An Open-label Pilot Study Evaluating the Effect of a Combination Regimen of Herceptin, Cisplatin, and Gemcitabine on Time to Disease Progression in Patients With Metastatic Urothelial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <authority>Germany: Bundesministerium f√ºr Gesundheit (Federal Ministry of Health)</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of a chemotherapy regimen of intravenous
      Herceptin, cisplatin and gemcitabine in patients with metastatic urothelial cancer. The
      anticipated time on study treatment is until disease progression.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2001</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time to progression</measure>
    <time_frame>approximately 4.5 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate: complete remission, partial remission, or stable disease</measure>
    <time_frame>approximately 4.5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>approximately 4.5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Incidence of adverse events</measure>
    <time_frame>approximately 4.5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Urinary Tract Cancer</condition>
  <arm_group>
    <arm_group_label>Herceptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trastuzumab [Herceptin]</intervention_name>
    <description>Initial dose of 4 mg/kg intravenously, followed by 2 mg/kg intravenously once weekly, until disease progression</description>
    <arm_group_label>Herceptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
    <description>1200 mg/m2 iv on Days 1, 8 and 15 of each 4-week cycle, 6 cycles</description>
    <arm_group_label>Herceptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>70 mg/m2 iv on Day 2 of each 4-week cycle, 6 cycles</description>
    <arm_group_label>Herceptin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patients with &gt;=18 years of age;

          -  metastatic urothelial carcinoma;

          -  measurable metastases or local recurrent disease;

          -  no prior chemotherapy for metastatic disease;

          -  HER2 overexpression (IHC [2+] or [3+]).

        Exclusion Criteria:

          -  concomitant chemotherapy or immunotherapy;

          -  active or uncontrolled infection;

          -  solely CNS metastases;

          -  clinically significant cardiac disease, advanced pulmonary disease or severe
             dyspnoea;

          -  co-existing malignancies diagnosed within last 5 years, except basal cell cancer or
             cervical cancer in situ.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Aschersleben</city>
        <zip>06449</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dessau</city>
        <zip>06846</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fulda</city>
        <zip>36043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leipzig</city>
        <zip>04277</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Weiden</city>
        <zip>92637</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 3, 2014</lastchanged_date>
  <firstreceived_date>December 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
